Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 1/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.42 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.42 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.42 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20281697 | 0.88 | CHEK2 (0.51) | CHEK2PDE4BUSP30PIK3CDGPR119 | |
| SCHEMBL21999105 | 0.87 | CHEK2 (0.53) | CHEK2PDE4BUSP30PIK3CDGPR119 | |
| SCHEMBL190497 | 0.87 | GPR119 (0.53) | CHEK2PDE4BGPR119 | |
| SCHEMBL29495616 | 0.87 | GPR119 (0.53) | CHEK2PDE4BGPR119 | |
| SCHEMBL26668746 | 0.84 | CHEK2 (0.55) | CHEK2PDE4BUSP30PIK3CDGPR119 | |
| SCHEMBL4005950 | 0.84 | CHEK2 (0.51) | CHEK2PDE4BUSP30PIK3CDGPR119 | |
| SCHEMBL13242428 | 0.83 | USP30 (0.51) | CHEK2PDE4BUSP30GPR119ANO1 | |
| SCHEMBL16771007 | 0.82 | CHEK2 (0.51) | CHEK2PDE4BUSP30PIK3CDGPR119 | |
| SCHEMBL16770949 | 0.82 | CHEK2 (0.51) | CHEK2PDE4BUSP30PIK3CDGPR119 | |
| SCHEMBL17061848 | 0.82 | CHEK2 (0.51) | CHEK2PDE4BUSP30PIK3CDGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1986645-B1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC (US) | 2012-01-04 | — | — | EP | disclosed |
| US-8022222-B2 | Glucokinase activators | ARRAY BIOPHARMA, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20090247526-A1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247526-A1 | GLUCOKINASE ACTIVATORS | GCKR, GCK, GALK1 | CHEK2 1337/4885PDE4B 2334/4885USP30 4174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.